CoChat

Inflammatory Markers in Schizophrenia: Comparing Antipsychotic Effects in Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study

Open access
Meyer, Jonathan M., McEvoy, Joseph P., Davis, Vicki G., Goff, Donald C., Nasrallah, Henry A., Davis, Sonia M., Hsiao, John K., Swartz, Marvin S., Stroup, T. Scott, Lieberman, Jeffrey A. · 2009 · Biological Psychiatry
Cited by 108

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Background C-reactive protein (CRP), intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin are systemic inflammatory markers (IM) that positively correlate with cardiovascular (CV) risk. Despite the known CV effects of atypical antipsychotics, there is limited prospective data on IM changes during treatment. Methods IM outcomes were compared between antipsychotic treatment groups in the CATIE Schizophrenia Trial phase 1 using subjects with laboratory assessments at baseline and 3 months (n=789). Results There were significant treatment differences in CRP, E-selectin and ICAM-1 at 3 months, with a differential impact of baseline values on the CRP and ICAM-1 results. In overall comparisons, quetiapine and olanzapine had the highest median levels for CRP, and olanzapine for E-selectin and ICAM-1. Olanzapine was significantly different after baseline adjustment than perphenazine (p=0.001) for E-selectin, and, in those with low baseline CRP (< 1 mg/L), olanzapine was significantly different than perphenazine (p<0.001), risperidone (p<0.001) and ziprasidone (p=0.002) for CRP. Perphenazine had the lowest 3-month ICAM-1 levels in subjects with baseline ICAM-1 above the median, but the differences were not statistically significant vs. olanzapine (p=0.010), quetiapine (p=0.010) and risperidone (p=0.006) after controlling for multiple comparisons. The 18-month repeated measures CRP analysis confirmed the significantly higher values for olanzapine in those with low baseline CRP. Conclusions This analysis provides further evidence for differential antipsychotic metabolic liabilities as measured by changes in systemic inflammation. CRP may emerge as a useful target for CV risk outcomes in schizophrenia patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.biopsych.2009.06.005

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 108

Metadata

Authors
Meyer, J. M., McEvoy, J. P., Davis, V. G., Goff, D. C., Nasrallah, H. A., Davis, S. M., Hsiao, J. K., Swartz, M. S., Stroup, T. S., & Lieberman, J. A.
Venue
Biological Psychiatry
Publisher
Elsevier BV
Published
2009-12
Volume
66
Issue
11
Pages
1013-1022
ISSN
0006-3223 (ISSN-L)
OpenAlex
W2081921819
Cited by
108
References
12
FWCI
6.09
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inflammatory Markers in Schizophrenia: Comparing Antipsychotic Effects in Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study. https://app.cochat.ai/papers/10.1016/j.biopsych.2009.06.005
The paper
Meyer, J. M., McEvoy, J. P., Davis, V. G., Goff, D. C., Nasrallah, H. A., Davis, S. M., Hsiao, J. K., Swartz, M. S., Stroup, T. S., & Lieberman, J. A. (2009). Inflammatory Markers in Schizophrenia: Comparing Antipsychotic Effects in Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study. Biological Psychiatry. https://doi.org/10.1016/j.biopsych.2009.06.005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.